In this interactive CME-certified activity, Charles G. Drake, MD, PhD, provides an overview of the use of immunomodulatory agents in the treatment of patients with cancer.
Upon completion of this activity, participants should be able to:
Improved Survival With Nivolumab vs DTIC in Treatment-naïve Pts With Advanced Melanoma Without a BRAF Mutation: CheckMate 066
Nivolumab Active With Manageable Toxicity in Previously treated Patients With Metastatic RCC
Nivolumab Active With Manageable Toxicity in Previously Treated Patients With Metastatic Renal Cell Carcinoma
Improved Survival With Nivolumab Compared With Dacarbazine in Treatment-Naive Patients With Advanced Melanoma Without a BRAF Mutation
MPDL3280A Safe and Effective in Pts With Locally Advanced or Metastatic UBC in Phase I Expansion Study
Conference CoverageEducationClinicalThoughtDecision SupportCCO Live EventsSlidesets & Resources
Disclaimer: The materials published on the Clinical Care Options Sites reflect the views of the reviewers or authors of the CCO material, not those of Clinical Care Options, LLC, the accredited provider, or the companies providing educational grants. The materials may discuss uses and dosages for therapeutic products that have not been approved by the United States Food and Drug Administration. A qualified healthcare professional should be consulted before using any therapeutic product discussed. Readers should verify all information and data before treating patients or using any therapies described in these materials.
Clinical Care Options, LLC. All Rights Reserved.